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osting by EAbstract Leptin is a fat derived hormone involved in the regulation of metabolism and body com-
position. The kidney is the principle organ responsible for elimination of circulating leptin. Our aim
is to evaluate if the nephrotic kidneys participate in the metabolism of leptin by comparing the serum
leptin level in renal veins and in their renal arteries and to study the relationship between leptin and
lipoprotein levels in healthy and nephrotic rats. Methods: Rats were divided into two equal groups:
group 1 in which experimental nephrotic syndrome was produced by injecting them intraperitoneally
with a supernatant of the homogenized mixture of their own kidney (obtained by previous unilateral
nephrectomy) and complete Freund’s adjuvant. Another group constituted the control group. Leptin
and lipid proﬁle were estimated in blood samples of renal veins and renal arteries. There was a highly
signiﬁcant increase in leptin and lipid proﬁle levels in the nephrotic rats compared with the normal
group. There was a high signiﬁcant decrease in leptin in the renal venous blood compared with its
level in the renal arterial blood of normal and nephrotic rats. This work has stressed the involvement
of kidney and the nephrotic renal tissue in the process of leptin metabolism and lipogenesis.
ª 2012 Academy of Scientific Research & Technology. Production and hosting by Elsevier B.V.
All rights reserved.tment ofMedical Biochemistry,
ir Street, Dokki, Cairo, Egypt.
(D.F. Habib).
iﬁc Research & Technology.
. All rights reserved.
enter, Egypt.
lsevier1. Introduction
Leptin (from the Greek word leptos, meaning thin) was ﬁrstly
identiﬁed in 1994. It is the product of ob gene [46]. It is a fat
derived hormone involved in the regulation of metabolism
and body composition [3]. Wasilewska et al. [43] demonstrated
that the kidneys play a key role in the systemic elimination of
circulating leptin. Leptin is not metabolized by the kidney but
is excreted as an intact protein. The mechanism involved is a
high capacity non-saturable process, most probably glomeru-
88 A.A. Fahmi et al.lar ﬁltration [4]. Nephrotic syndrome (NS) is a well recognized
renal disorder of varied etiology; and is characterized by a spe-
cial plasma lipids and lipoproteins proﬁle. Impaired renal
function is found in nephrotic syndrome. Landt et al. [24]
found a relationship between impaired renal function and
abnormal leptin metabolism [20].
Leptin concentrations are increased in the plasma of pa-
tients with end-stage renal disease and chronic renal failure
[27]. An increased protein ﬁltration in nephrotic syndrome in-
creases urinary leptin excretion. However, the increased leptin
loss in the urine is not always accompanied by a decrease in
serum levels[40]. Kovesdy et al. [23] found elevated leptin level
in kidney transplant recipients.
Wasilewska et al. [43] found increased urinary leptin excre-
tion in patients with nephrotic syndrome accompanied by nor-
mal serum levels. Another important mechanism which may be
involved in this process is the role of soluble leptin receptor in
serum of nephrotic patients. It was found that levels of soluble
leptin receptor, identiﬁed as leptin binding protein, were signif-
icantly higher in nephrotic patients than in controls and
patients in remission [4]. Other investigators had observed an
increase in urinary leptin excretion concomitant with a
reduction in the serum level [28]. In nephrotic syndrome chil-
dren leptin urinary excretion increases but its level in serum
is unchanged. Serum leptin level is correlated with lipid param-
eters [43].
Ece et al. [10] demonstrated that plasma leptin levels in
(NS) remain controversial. Leptin structurally resembles a
cytokine and a number of animal studies suggest a link be-
tween inﬂammation and elevated leptin levels [34,13]. Leptin’s
role in the regulation of lipid metabolism has not been com-
pletely elucidated [16,44,38].
Wu et al. [44] showed in healthy children a positive correla-
tion of serum leptin level with triglycerides (TG), intermedi-
ate-density lipoprotein (IDL) and apolipoprotein B (apo B),
and a negative correlation with high-density lipoprotein
(HDL) and apolipoprotein A (apo A). Other authors showed
a positive correlation between leptin, triglycerides (TG), apoli-
poprotein B (apo B) [33,44,43].
Dashti et al. [8] concluded that the kidney contributes to
clearance of circulating leptin in humans and further studies
are required to evaluate the signiﬁcance of these elevated leptin
levels in relation to indices of appetite in patients with end-
stage renal disease. Future research should also focus on eluci-
dating the etiology of the inﬂammation and studying the long-
term effects of various anti-inﬂammatory treatment strategies
on nutritional and cardiovascular status as well as outcome
in end-stage renal disease (ESRD) patients.
Many workers suggested that liver is the source of the ele-
vated plasma lipids in nephrotic syndrome [25,2]. Nicola et al.
[30,31], suggested that nephrotic kidney is a source of elevated
lipids proﬁle in view of the signiﬁcantly increased lipids proﬁle
level in the nephrotic renal venous blood than in the nephrotic
renal arterial blood.
The aim of this work is to evaluate if the nephrotic kidneys
participate in the metabolism of leptin by comparing the ser-
um leptin level in renal veins with that in the renal arteries of
rats with nephritic syndrome and to study the relationship be-
tween leptin and lipoprotein levels in healthy and nephrotic
rats.2. Materials and methods
Thirty male albino rats weighed from 160 to 190 g, taken from
the animal house of the National Research Centre, were used.
The rats were fed on a stock diet composed of whole wheatmeal,
skimmed milk powder, ﬁsh ﬂour, dry yeast, stabilized vitamin
A, D and NDP energy of 12% [29]. Diet was given in plenty
to the rats throughout the experimentation period (for
3 months) Animals were provided with water ad-libitum. The
animal experiments were done in accordance with the regula-
tions of the Ethical Committee of theNationalResearchCentre.
2.1. Study design
The rats were divided into two equal groups (each group: 15
rats): Group I: Control group I, 15 healthy male rats served
as healthy controls. The other group (Group II) had their kid-
neys made nephrotic by injecting them intraperitoneally with
0.2 cc low speed supernatant (3000–4000 rpm for 1–1.5 h) of
1:2 blood free own kidney in saline obtained by previous uni-
lateral nephrectomy with 0.3 Freund’s complete adjuvant (is
an antigen emulsiﬁed in mineral oil, used to stimulate produc-
tion of tumor necrosis factor). Blood samples of their levels in
their renal veins with those in their venous blood and also with
those of normal control rats. Each rat was injected whole six
injections one each 14 days) after the technique of [18].
2.2. Unilateral nephrectomy
General anesthesia of rats was done through inhalation of di-
ethyl ether, after anesthesia, the hair at the site of operation
was clipped and shaved then washed by soap and water, and
disinfected by alcohol 70%, followed by Tincture iodine 4%.
A longitudinal incision in the skin and muscles was made,
and by blunt forceps the wound was widened till appearance
of the kidney. Strong ligation to the renal artery and renal vein
were made separately followed by excision of kidney. After
nephrectomy, coaptation of the wound occurred by lemberet’s
sutures. Intraperitoneal injections of operated rats had been
done after complete recovery for about four weeks.
Blood was collected from renal artery and renal vein by
using syringe into dry clean test tubes, then allowed to clot
and centrifuged at 4000 rpm for 10 min to separate the serum.
Serum was collected into dry clean test tubes; glucose and low
density lipoprotein (LDL-cholesterol) were determined imme-
diately. The rest of serum was frozen at 20 C for the subse-
quent estimation of the other parameters.
2.3. Estimation of serum leptin
Leptin was estimated by an immunoenzymometric assay for
the quantitative measurement of human leptin in serum and
plasma ‘‘The Biosource Leptin Enzyme Ampliﬁed Sensitivity
Immuno assay (EASIA)’’. The kit was supplied by BioSource
Europe SA, rue de l’ Industrie 8 B-1400 Nivelles Belgium.
2.4. Determination of serum total cholesterol
Total cholesterol was determined using the enzymatic method
of Allain et al. [1]. Using the total cholesterol kit of Bio-Merieux
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L’Etoile/France.
2.5. Determination of serum triglycerides
Serum triglycerides were determined by the quantitative enzy-
matic calorimetric determination of triglycerides according to
Wahlefeld [42] by using Stanbio Enzymatic, 2930 East Hous-
ton Street, San Antonio, Texas 78202, USA.
2.6. Determination of serum phospholipids
Serum phospholipid was determined by enzymatic method
according to Trinder [39] using phospholipids kit of Quimica
Clinica Aplicada 43870 Amposta/Tarragona. Espana.
2.7. Determination of serum HDL-cholesterol
Was done according to Glatter equation, Glatter [14] where:
Serum HDL-Cholesterol ¼ Total cholesterol Triglyceride
5
 LDL-Cholesterol2.8. Determination of serum LDL-cholesterol
Serum LDL cholesterol was determined after Steinberg [37] by
using LDL cholesterol/phospholipids kit of Bio Merieux labo-
ratory reagents and products Bio Merieux 69280 Marcy-1,
Etoile/France.
2.9. Determination of serum VLDL-cholesterol
According to Glatter equation, Glatter [14] where
SerumVLDLCholesterol ¼ Triglycerides
52.10. Determination of serum apolipoprotein A-1 and B
Apolipoprotein A-1 and B were estimated by immunoprecipi-
tin analysis method according to Finley et al. [11]. Apo A-1
kits obtained from Atlantic Antibodies, An INCSTAR Com-
pany INCSTAR corporation-Stillwater, Minnesota, USA.
2.11. Statistical analysis of data
Data are expressed as mean ± SE. Statistical signiﬁcance of
the difference was analyzed using one way-ANOVA and
post-hoc Duncans’ test for multiple group comparison. P val-
ues of <0.05 were considered statistically signiﬁcant. The cor-
relation coefﬁcient (r) which is a measure of the degree of
closeness of the linear relationship between two variables (X
and Y) was determined, r always lies between 1 and +1.
3. Results
There was a highly signiﬁcant decrease in leptin level in renal
veins compared with its level in renal arteries of normal rats.There was also a non signiﬁcant rise in apolipoprotein A-1
and apolipoprotein B value in renal veins compared with the
values in renal arteries blood of normal rats. High signiﬁcant
decrease in leptin level was seen in renal veins compared with
renal arteries of nephrotic rats. In addition, we observed a
highly signiﬁcant increase in apolipoprotein A-1 and apolipo-
protein B in renal veins compared with the renal arteries of
nephrotic rats (Table 1). There was also a high serum leptin,
apolipoprotein A-1 and apolipoprotein B levels in the nephro-
tic rats compared with the normal controls (Table 1). There
was an insigniﬁcant change in lipid proﬁle between the renal
vein compared with renal artery blood of normal rats (Table
2), but a signiﬁcant rise in lipid proﬁle in the renal vein com-
pared with its level in renal artery of nephrotic rats (Table
2). There was also a high serum lipid proﬁle level in the
nephrotic rats compared with the normal controls (Table 2).
Table 3 shows the correlation between renal arterial serum lep-
tin and lipids in normal control and nephrotic rats. Table 4
shows the correlation between renal venous serum leptin and
lipids in normal control and nephrotic rats.4. Discussion
In the present work, there is a high signiﬁcant decrease in lep-
tin in the renal venous blood than in the renal arterial blood
of normal rats (Table 1). This is mainly because the kidneys
play a principal role in the elimination of this peptide [36].
The kidney is the principle organ responsible for elimination
of circulating leptin. Arteriovenous balance studies in rodents
and humans showed that the kidney efﬁciently extracted leptin
from the renal circulation [24]. Many authors demonstrated
that endogenous leptin is rapidly cleared from the circulation
by the kidney by glomerular ﬁltration followed by metabolic
degradation in the renal tubules [43,35,6]. However few
authors reported that leptin is not metabolized by the kidney
but is excreted as an intact protein. The mechanism involved is
a high capacity non-saturable process, most probably glomer-
ular ﬁltration [4].
In the present work, there was a high signiﬁcant decrease in
leptin in the renal venous blood than in the renal arterial blood
of nephrotic rats (Table 1). This is due to increasing of leptin
urinary excretion and which agrees with Wasilewska et al.
[43] who demonstrated that in nephrotic children; leptin uri-
nary excretion increases. It was also suggested that the signif-
icant loss of leptin in proteinuric patients is compensated by
sustained upregulation of leptin production [35].
Impaired renal function is found in nephrotic syndrome
and Landt et al. [24] found relationship between impaired re-
nal function and abnormal leptin metabolism [4].
The cascade of events responsible for leptin catabolism by
the kidneys is unknown. The failure of leptin to appear imme-
diately in urine after bolus injection is inconsistent with the
hypothesis that leptin is eliminated by simple glomerular ﬁltra-
tion alone. The results of these kinetic studies suggest that re-
nal metabolism of leptin could involve active uptake of leptin
by renal tissues. The study of Cumin et al. [7] concluded that
glomerular ﬁltration was the important mechanism for renal
elimination of leptin [45].
In the present work, there are high serum leptin levels in the
nephrotic rats compared with the normal controls (Table 1).
Table 1 Serum leptin, apolipoprotein A-1 (Apo A-1) and apolipoprotein B (Apo B) levels in renal venous (RV) and renal arterial
(RA) blood in different experimental groups.
Group (n= 9) Leptin (ng/ml) Apo A-1 (mg/dl) Apo B (mg/dl)
RA-control 2.48 ± 0.057 47.68 ± 0.38 34.01 ± 0.41
RV-control 2.16 ± 0.033a 47.01 ± 0.26 34.46 ± 0.36
RA-nephrotic 3.68 ± 0.054b 103.57 ± 0.42b 79.98 ± 0.37b
RV-nephrotic 3.51 ± 0.048c,d 120.46 ± 0.54c,d 89.97 ± 1.02c,d
Statistical differences were observed between:
a p< 0.05, RA-control and RV-control.
b p< 0.05, RA-control and RA-nephrotic.
c p< 0.05, RA-nephrotic and RV-nephrotic.
d p< 0.05, RV-control and RV-nephrotic.
Table 2 Serum lipid fractions in renal venous (RV) and renal arterial (RA) blood in different experimental groups.
Group (n= 9) TC (mg/dl) TG (mg/dl) Phosph (mg/dl) LDL (mg/dl) HDL (mg/dl) VLDL (mg/dl)
RA-control 80.16 ± 1.52 66.62 ± 0.63 132.87 ± 0.1 28.08 ± 1.56 38.76 ± 0.33 13.32 ± 0.13
RV-control 81.27 ± 1.38 66.68 ± 0.64 133.96 ± 0.9 28.80 ± 1.44 38.92 ± 0.27 13.34 ± 0.42
RA-nephrotic 135.38 ± 2.61a 153.71 ± 1.49a 201.80 ± 1.78a 58.64 ± 2.11a 45.99 ± 0.57a 30.74 ± 0.3a
RV-nephrotic 164.57 ± 2.01b,c 230.90 ± 2.16b,c 255.99 ± 1.64b,c 65.42 ± 2.39b,c 53.45 ± 0.48b,c 46.2 ± 1.4b,c
TC, total cholesterol; TG, triglycerides; Phosph, phospholipids; LDL, low-density lipoprotein.
HDL, high-density lipoprotein; VLDL, very low-density lipoprotein.
Statistical differences were observed between:
a p < 0.05, RA-control and RA-nephrotic.
b p< 0.05, RA-nephrotic and RV-nephrotic.
c p< 0.05, RV-control and RV-nephrotic.
Table 3 Correlation between renal arterial serum (RA) leptin and serum lipids in normal control and nephrotic rats.
Group TC TG Phosph HDL LDL VLDL Apol A-1 Apo B
RA-control (n= 9) r 0.403 0.928 0.174 0.244 0.980 0.075 0.318 0.214
P <0.05 <0.01 NS NS <0.01 NS NS NS
RA-nephrotic (n= 8) r 0.026 0.164 0.081 0.095 0.044 0.163 0.186 0.507
P NS NS NS NS NS NS NS <0.05
r, correlation coefﬁcient; TC, total cholesterol; TG, triglycerides; Phosph, phospholipids; LDL, low-density lipoprotein, HDL, high-density
lipoprotein; VLDL, very low-density lipoprotein; APO A-1, apolipoprotein A-1; Apo B, apolipoprotein B.
Table 4 Correlation between renal venous (RV) serum leptin and serum lipids in normal control and nephrotic rats.
Group TC TG Phosph HDL LDL VLDL Apol A-1 Apo B
RV-control Leptin r 0.195 0.907 0.182 0.479 0.955 0.0123 0.387 0.666
P NS <0.01 NS <0.05 <0.01 NS NS <0.05
RV-nephrotic Leptin r 0.283 0.428 0.337 0.453 0.345 0.428 0.142 0.020
P NS <0.05 NS <0.05 NS <0.05 NS NS
r, correlation coefﬁcient; TC, total cholesterol; TG, triglycerides; Phosph, phospholipids; LDL, low-density lipoprotein; HDL, high-density
lipoprotein; VLDL, very low-density lipoprotein; Apo A-1, apolipoprotein A-1; Apo B, apolipoprotein B.
90 A.A. Fahmi et al.Many authors demonstrated that no signiﬁcant difference
in plasma leptin concentrations between the healthy subjects
and nephrotic patients [17,43,32].
However; Huang et al. [19] demonstrated that high levels of
leptin can be caused by the delayed clearance of leptin from
circulation due to the binding to its soluble receptor. They con-
cluded that sOB-R is up-regulated and an over-expression ofsOB-R results in an increase of circulating leptin in nephrotic
syndrome [17]. These results are in accordance with the results
of the present work. We add that our method of induction of
nephrotic syndrome used unilateral nephrectomized rats so the
amount of clearance and elimination of leptin by one kidney is
less than that by two kidneys. This leads to increase of leptin in
our ﬁnding.
Renal leptin in experimental nephrotic syndrome 91Cohen et al. [5] indicated that the liver is a major source of
plasma-soluble leptin receptor (SLR) expression in states of
negative energy balance and demonstrate a novel role for the
liver in modulating leptin action. The data showed that the
relationship between leptin and lipid levels in patients with
chronic glomerulonephritis is limited [26].
Wu et al. [44] demonstrated a positive correlation between
serum leptin and triglyceride and LDL levels in healthy chil-
dren, and a negative correlation between serum leptin and
HDL; this coordinates with our ﬁnding in our control rats
(Tables 3 and 4). Research suggested that there is a relation-
ship between leptin concentration and certain markers of the
metabolic syndrome, including cholesterol, triglycerides and
apolipoproteins [12,44,38]. A substantial disturbance of lipid
metabolism occurs in children with idiopathic nephrotic syn-
drome [9,41]. Haluzik et al. [15] concluded that serum leptin
levels in most types of hyperlipidemia simply reﬂect the degree
of adiposity expressed by BMI and are not clearly related to
serum lipid and/or lipoprotein concentrations. Our results
coordinate with Wasilewska et al. [43] who reported a positive
correlation of leptin with total cholesterol, its LDL fraction
and HDL fraction and a negative correlation with apo A
and apo B in nephrotic children (Tables 3 and 4). However
our results are not in agreement with them in correlation of
leptin with triglyceride which a negative correlation in renal
arterial blood and a positive correlation in renal venous of
nephrotic rats (Tables 3 and 4).
Literature data referring to the relationship between serum
leptin level and lipid fractions in nephrotic patients are scarce.
Ozata et al. [32] found no correlation of leptin with plasma TG
or other lipid parameters in nephrotic subjects. Thus, their
data suggest that plasma leptin levels are normal in the
nephrotic syndrome and do not play a role in the dyslipidemia
observed in this syndrome.
Nephrotic syndrome is a well recognized renal disorder of
varied etiology; and is characterized by a special plasma lipids
and lipoproteins proﬁle whatever the cause is. This lipids and
lipoproteins proﬁle shows hypercholesterolemia, raised LDL
and VLDL pattern, and decreased HDL concentration [21].
The latter is especially manifest in human nephrotic syndrome
[22].
This characteristic lipid proﬁle in face of the varied etiology
of the syndrome led Nicola et al. [30,31] to study the role of the
kidney tissue in the genesis of plasma lipids in this characteris-
tic pattern.
There is a highly important increase in serum lipids, lipo-
protein fractions, apo A-1, apo B of nephrotic rats when com-
pared with the control group, but the point is that, all these
parameters were signiﬁcantly increased in the renal venous
blood of the nephrotic rats than in their renal arterial blood,
a ﬁnding which was not seen in the control group. These
results prove that kidney plays a role in lipogenesis in
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